These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29260740)

  • 1. [Hepatitis C can be cured: will hepatitis B become next?].
    Chulanov VP; Zueva AP; Kostyushev DS; Brezgin SA; Volchkova EV; Maleyev VV
    Ter Arkh; 2017; 89(11):4-13. PubMed ID: 29260740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
    Yang YC; Yang HC
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
    Kennedy EM; Kornepati AV; Cullen BR
    Antiviral Res; 2015 Nov; 123():188-92. PubMed ID: 26476375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
    Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
    Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
    Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
    World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we cure hepatitis B virus with novel direct-acting antivirals?
    Martinez MG; Villeret F; Testoni B; Zoulim F
    Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo].
    Kostyusheva AP; Brezgin SA; Ponomareva NI; Goptar IA; Nikiforova AV; Gegechkori VI; Poluektova VB; Turkadze KA; Sudina AE; Chulanov VP; Kostyushev DS
    Mol Biol (Mosk); 2022; 56(6):884-891. PubMed ID: 36475475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current status and future directions of hepatitis B antiviral drug discovery.
    Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
    Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antivirals for the treatment of chronic hepatitis B.
    Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
    Peng C; Lu M; Yang D
    Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future anti-HBV strategies.
    Gane EJ
    Liver Int; 2017 Jan; 37 Suppl 1():40-44. PubMed ID: 28052637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection.
    Ely A; Singh P; Smith TS; Arbuthnot P
    Adv Drug Deliv Rev; 2021 Jan; 168():134-146. PubMed ID: 32485207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a new era of hepatitis B virus therapeutics: The pursuit of a functional cure.
    Tsounis EP; Tourkochristou E; Mouzaki A; Triantos C
    World J Gastroenterol; 2021 Jun; 27(21):2727-2757. PubMed ID: 34135551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
    Guo JT; Guo H
    Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.